ARWR — Arrowhead Pharmaceuticals, Inc.

Is ARWR overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Oversold As of November 17, 2026

Arrowhead Pharmaceuticals, Inc. (ARWR) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $42.99. The rating moved from Strong Oversold to Oversold on November 12, 2026.

See all oversold Healthcare stocks →

AI analysis

Arrowhead is a pipeline‑centric RNAi biotech with multiple near‑term catalysts from clinical readouts and potential partner/M&A interest. The platform and program diversity create upside if data are positive and support strategic transactions. However, the company remains exposed to binary clinical/regulatory outcomes, cash‑burn dynamics and competitive pressure. Near‑term market conditions are calm, which may permit measured appreciation into positive newsflow, while any adverse results or financing needs would likely drive outsized downside.

Key factors

  • Proprietary RNAi platform and diversified pipeline across multiple indications provide multiple binary catalysts and potential high-value licensing or partnership outcomes.
  • Upcoming clinical data readouts and program milestones that could materially re-rate the shares if positive.
  • Strategic partner interest and an acquisitive large‑cap pharma environment increase the likelihood of collaboration or M&A opportunities.
  • Market technical backdrop is calm with selective support for growth biotechs, reducing near-term volatility from macro-driven shocks.
  • Existing cash runway and prior financing/partnering experience reduce near-term dilution risk relative to earlier-stage peers (subject to confirmation from filings).

Risks

  • Clinical trial failures, disappointing efficacy/safety readouts, or delayed enrollment that would materially impair program valuations.
  • Regulatory setbacks or more onerous approval requirements for novel RNAi therapeutics that could increase development timelines and costs.
  • Cash burn and the potential need for dilutive financing if milestone payments/partnerships do not materialize on schedule.
  • Competition from other RNAi, ASO, gene‑editing and biologic platforms that could limit market share or partner interest.
  • Market sentiment volatility and sector-wide rotations that can sharply compress small/ mid‑cap biotech valuations independent of fundamentals.
  • Limited observable social sentiment and sparse near‑term public disclosure increase information asymmetry for investors.

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for ARWR — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.